Roche in-licenses USP-1 small molecule to PARP inhibitorJuly 13, 2023 - " USP1 is one of a clutch of emerging targets for synthetic lethality, an approach to killing cancer cells that PARP inhibitors such as AstraZeneca and Merck & Co.’s Lynparza have helped put on the map over the past decade. While PARP inhibitors have validated the concept, they are unable to trigger responses in all patients and are vulnerable to resistance even when they are initially effective. Roche has identified the candidate as a good fit for its pipeline. "
https://www.fiercebiotech.com/biotech/roche-finds-usp-cancer-inking-deal-ksq-expand-stable-synthetic-lethal-candidates
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6420636/